medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 5

<< Back Next >>

Ann Hepatol 2015; 14 (5)

Fatty liver and abdominal fat relationships with high C-reactive protein in adults without coronary heart disease

Cardoso-Saldaña GC, Medina-Urrutia AX, Posadas-Romero C, Juárez-Rojas JG, Jorge-Galarza E, Vargas-Alarcón G, Posadas-Sánchez R

Language: English
References: 43
Page: 658-665
PDF size: 130.68 Kb.


ABSTRACT

Background and rationale. Fatty liver (FL) and abdominal visceral fat (AVF) are strongly associated with systemic inflammation, however, it has not been defined if each one is independently involved, and if the insulin resistance is associated. To investigate if FL, AVF and insulin resistance are independently or additively associated with the high-sensitivity C-reactive protein (hs-CRP) in subjects without coronary artery disease we included 491 men and 553 women. Material and methods. All had anthropometric and plasma biochemical measurements, FL and AVF assessments by computed tomography. Results. The FL prevalence was 35.6% in men and 28.0% in women, p ‹ 0.01. The prevalence of obesity, metabolic syndrome and homeostasis model assessment of insulin resistance (HOMA-IR) was significantly higher in FL compared to non FL subjects. FL and AVF accounted for 21 and 17%, respectively, to hs-CRP plasma levels. FL, AVF ≥ P75 and HOMA-IR ≥ P75 were independently and additively associated with plasma hs-CRP. The risk of hs-CRP ≥ 3 mg/L increased progressively in men from 1.36 (0.5-3.86) through 3.58 (1.32-9.7) in those with 1 or 3 factors respectively. In women from 2.25 (1.2-4.2) to 4.67 (2.3-9.4), respectively. In conclusion, both the FL and hs-CRP ≥ 3 mg/L occur in 1 of every 3 non CAD subjects. In men, FL and AVF ≥ P75 were associated with 3.6 times the risk of hs-CRP ≥ 3 mg/L, while in women, these factors were independently and additively associated with a 4.7 times higher risk of systemic inflammation.


REFERENCES

  1. Thakur ML, Sharma S, Kumar A, Bhatt SP, Luthra K, Guleria R, Pandey RM, et al. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians. Atherosclerosis 2012; 223: 507-11.

  2. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 3-16.

  3. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Hearth J 2012; 33: 1190-200.

  4. Ampuero J and Romero-Gómez M. Influencia de la enfermedad por hígado graso no alcohólico en la enfermedad cardiovascular. Gastroenterol Hepatol 2012; 35: 585-93.

  5. Assy N, Djibre A, Farah R, Grosovski M and Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 2010; 254: 393-400.

  6. Speliotes EK, Massaro JM, Udo Hoffmann U, Vasan RS, Meigs JB, Sahani DV, Hirschhorn JN, et al. Fatty Liver is Associated With Dyslipidemia and Dysglycemia Independent of Visceral Fat: The Framingham Heart Study. Hepatology 2010; 51: 1979-87.

  7. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106: 15430-5.

  8. Liu J, Musani SK, Bidulescu A, Carr JJ, Wilson JG, Taylor HA, Fox CS. Fatty liver, abdominal adipose tissue and atherosclerotic calcification in African Americans: the Jackson Heart Study. Atherosclerosis 2012; 224: 521-5.

  9. Sung KC, Wild SH, Kwag HJ, Byrne CD. Fatty liver, insulin resistance, and features of metabolic syndrome: relationship with coronary artery calcium in 10,153 people. Diabetes Care 2012; 35: 2359-64.

  10. Lavie CJ, Milani RV, Verma A, O’Keefe JH. C-reactive protein and cardiovascular diseases—is it ready for primetime? Am J Med Sci 2009; 338: 486-92.

  11. Haukeland JW, Damas JK, Konopski Z, Løberg EM, Haaland T, Goverud I, Torjesen PA, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006; 44: 1167-74.

  12. Ndumele CE, Nasir K, Conceiçao RD, Carvalho JA, Blumenthal RS, Santos RD. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Atheroscler Thromb Vasc Biol 2011; 31: 1927-32.

  13. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, Muggeoso M, et al. NASH Predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity 2008; 16: 1394-9.

  14. Lizardi-Cervera J. Association among C-reactive protein, fatty liver disease, and cardiovascular risk. Dig Dis Sci 2007; 52: 2375-9.

  15. Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N, Miyauchi K. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem 1995; 41: 717-23.

  16. DeLong DM, DeLong ER, Wood PD, Lippel K, Rifkind BM. A comparison of methods for the estimation of plasma lowand very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study. JAMA 1986; 256: 2372-7.

  17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.

  18. Sjöström L, Kvist H, Cederblad A, Tylén U. Determination of total adipose tissue and body fat in women by computed tomography, 40K, and tritium. Am J Physiol 1986; 250: E736-E745.

  19. Kvist H, Chowdhury B, Grangard U, Tylén U, Sjöström L. Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations. Am J Clin Nutr 1988; 48: 1351-61.

  20. Ricci C, Longo R, Gioulis E, Bosco M, Pollesello P, Massutti F, Croce LS, et al. Non invasive in vivo quantitative assessment of fat content in human liver. J Hepatol 1997; 27: 108-13.

  21. Piekarski J, Goldberg HI, Royal SA, Axel L, Moss AA. Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology 1980; 137: 727-9.

  22. Sánchez-Castillo CP, Velázquez-Monroy O, Berber A, Lara- Esqueda A., Tapia-Conyer R, James WP. Encuesta Nacional de Salud (ENSA) 2000 Working Group. Anthropometric cutoff points for predicting chronic diseases in the Mexican National Health Survey 2000. Obes Res 2003; 11: 442-51.

  23. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.

  24. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.

  25. Baecke JA, Barema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 1982; 36: 936-42.

  26. Iwasaky T, Nakajima A, Yoneda M, Terauchi Y. Relationship between the serum concentrations of C-reactive protein and parameters of adiposity and insulin resistance in patients with type 2 diabetes mellitus. Endocrine J 2006; 53: 345-56.

  27. Lemieux I, Pascot A, Prud’homme D, Alméras N, Bogaty P, Nadeau A, Bergeron J, et al. Elevated C-reactive protein another component of the atherotrombotic profile of abdominal obesity. Atheroscler Thromb Vasc Biol 2001; 21: 961-7.

  28. Sobhonslidsuk A, Jongjirasiri S, Thakkinstian A, Wisedopas N, Bunnag P, Puavilai G. Visceral fat and insulin resistance as predictor of non-alcoholic steatohepatitis. World J Gastroenterol 2007; 13: 3614-8.

  29. Cusi K. Role of insulin resistance and lipotoxicity in nonalcoholic steatohepatitis. Clin Liver Dis 2009; 13: 545-63.

  30. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol 2010; 25: 672-90.

  31. Kolak M, Westerbacka J, Velagapudi VR, Wagsäter D, Yetukuri L, Makkonen J, Rissanen A, et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007; 56: 1960-8.

  32. Pagadala M, Kasumov T, McCullough AJ, Zein NN, Kirwan JP. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab 2012; 23: 365-71.

  33. Fon Tacer K, Rozman D. Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation. J Lipids 2011: 783976. doi: 10.1155/2011/783976.

  34. Park S, Kim M, Paik JK, Jang YJ, Lee SH, Lee JH. Oxidative stress is associated with C-reactive protein in nondiabetic postmenopausal women, independent of obesity and insulin resistance. Clin Endocrinol (Oxf) 2013; 79: 65-70.

  35. Lakoski SG, Gender and C-reactive protein: data from the multiethnic study of atherosclerosis (MESA) cohort. Herat J 2006;152: 593-8.

  36. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels-a prospective and cross-sectional evaluation. Atherosclerosis 2002; 165: 285-92.

  37. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diab Care 2002; 25: 2016-21.

  38. Thorand B, Baumert J, Döring A, Herder C, Kolb H, Rathmann W, Giani G, et al. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 2006; 184: 216-24.

  39. Clark CR, Ridker PM, Ommerborn MJ, Huisingh CE, Coull B, Buring JE, Berkman LF. Cardiovascular inflammation in healthy women: multilevel associations with state-level prosperity, productivity and income inequality. BMC Public Health 2012; 12: 211. doi: 10.1186/1471-2458-12-211.

  40. Modena MG, Bursi F, Fantini G, Cagnacci A, Carbonieri A, Fortuna A, Rossi R. Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen. Am J Med 2002; 113: 331-4.

  41. Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004;110: 380-5.

  42. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.

  43. Park SH, Kim KW, Lee SW, Yoon SE, Park SW, Ha HK, Lee MG, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006; 239: 105-12.




2020     |     www.medigraphic.com